Update from the AAN Conference: Clinical Insights on Multiple Sclerosis Management from AAN 2016
Boston, Massachusetts (PRWEB) April 21, 2016 -- In the past decade, the MS treatment landscape has advanced dramatically and continues to rapidly evolve. An increasing number of disease-modifying therapies (DMTs) slow disease progression by preventing acute exacerbations and new lesion formation. This year’s annual meeting of the American Academy of Neurology (AAN), to be held in Vancouver, British Columbia, Canada, April 15-21, 2016, is the premier meeting for clinicians and researchers in neurology and a key meeting for those involved in MS care and research. The 2016 AAN meeting will attract nearly 14,000 attendees and will include nearly 700 abstracts in this area.
This seminal meeting is of the utmost importance to clinicians because of its coverage on MS diagnosis and disease evaluation, underlying pathophysiology, current and emerging therapies, and other management strategies. Expert commentary on key presentations from AAN will be presented live-online, affording clinicians a live Q&A with the experts immediately following the meeting.
Fred Lublin, MD, Saunders Family Professor of Neurology from the Mount Sinai Hospital, and Patricia K Coyle, MD, Professor and Acting Chair, Department of Neurology from Stony Brook University, will review the biggest stories in MS from the 2016 AAN conference in a one-hour online CME program hosted by NeuroSerieslive.com.
Attendees will receive MS updates from AAN to better be able to: evaluate recent clinical trial data and efficacy of current and emerging DMTs for MS; apply appropriate treatment selection their MS patients; and develop individualized, evidence-based treatment plans for MS patients based on the most up-to-date, expert-recommended therapy selection strategies – including when and how to advance MS therapy, and managing actively or aggressive progressing disease.
We recommend this CME program neurologists, neurology nurses, nurse practitioners and physician assistants, as well as primary care clinicians who manage patients with multiple sclerosis.
The complimentary, online CME session will take place Tuesday, April 26th, 2016 1:00 PM – 2:00 PM EST at NeuroSeriesLive.com. This activity is supported by educational grants from Genentech.
CEO Robert Rosenbloom said, “Providing up-to-date, expert guidance on what’s new in MS can’t be done without covering the most important annual Neurology event in the world. We’re excited to provide clinicians the insights and online platform to get answers quickly that will help improve treatment options for their patients in the coming year.”
NeuroSeries Live delivers neurologists and other clinicians treating patients with neurological diseases a unique online learning platform that empowers clinical learners to questions and get immediate answers from experts about MS. The neurology channel of PlatformQ Health, NeuroSeries Live designs all its programs to be interactive throughout, so the physicians will be replying to questions throughout the presentation. Attendees can also give their opinion on best medical practices via in-session polls throughout the session.
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Albert Einstein College of Medicine and Montefiore Medical Center and PlatformQ Health Education, LLC. The Albert Einstein College of Medicine and Montefiore Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
Christian Rubio, OMedLive.com, http://omedlive.com, +1 (617) 938-6059, [email protected]
Share this article